<doc>
  <docmeta id="113s2689is">
    <bill congress="113" type="s" number="2689" version="is"/>
    <revision size="13222" annotations="0" status="complete" id="6" commit-time="2014-08-11T22:41:42Z" committer="mbohmer" doc="113s2689is/6.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 S2689 IS: Medicare CGM Access Act of 2014</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. Senate</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-07-30</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
    <session>2d Session</session>
		<legis-num>S. 2689</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20140730">July 30, 2014</action-date>
			<action-desc>
        <sponsor name-id="S252">Ms. Collins</sponsor> (for herself and <cosponsor name-id="S324">Mrs. Shaheen</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend title XVIII of the Social Security Act to specify coverage of continuous glucose
			 monitoring devices, and for other purposes.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
			<text display-inline="no-display-inline">This Act may be cited as the
		  <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare CGM Access Act of 2014" proposed="true">Medicare CGM Access Act of 2014</cato:entity-ref>
          </short-title>
        </quote>.</text>
    </section>
    <section id="ida19d8d31d2c5465f9468cc5cb591424e">
      <enum>2.</enum>
      <header>Medicare coverage of continuous glucose monitoring devices</header>
      <subsection id="idc71eb9edc323493f9a665395958ed4b4">
        <enum>(a)</enum>
        <header>In general</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Social Security Act/s:1861">Section 1861 of the Social Security Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">
            <cato:entity-ref entity-type="uscode" value="usc/42/1395x">42 U.S.C. 1395x</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text>
        <paragraph id="ide851762c52824a6e8e3ab8c6cb63e79c">
          <enum>(1)</enum>
          <text>in subsection (s)(2)—</text>
          <subparagraph id="id38daa3dff42c4594aed44106ed86e089">
            <enum>(A)</enum>
            <text>in subparagraph (EE), by striking <quote>and</quote> at the end;</text>
          </subparagraph>
          <subparagraph id="idc3860b50fcad485fb7d426e1925383c4">
            <enum>(B)</enum>
            <text>in subparagraph (FF), by adding <quote>and</quote>; and</text>
          </subparagraph>
          <subparagraph id="idaff3d1c091e745afbe31302db2c9178b">
            <enum>(C)</enum>
            <text>by adding at the end the following new subparagraph:</text>
            <quoted-block display-inline="no-display-inline" id="ide618f1f538a9442693b4e73369a669e7" style="OLC">
              <subparagraph id="idc47505fe5f85431495251ccd8772afef" indent="up1">
                <enum>(GG)</enum>
                <text>continuous glucose monitoring devices (as defined in subsection (iii)(1)) furnished to a CGM
			 qualified individual (as defined in subsection (iii)(2));</text>
              </subparagraph>
              <after-quoted-block>; and</after-quoted-block>
            </quoted-block>
          </subparagraph>
        </paragraph>
        <paragraph id="idca750b6f43aa4278a895a3d14f018eec">
          <enum>(2)</enum>
          <text>by adding at the end the following new subsection:</text>
          <quoted-block display-inline="no-display-inline" id="idd0ff7b12a5644b979921b5d330bead82" other-style="archaic" style="other">
            <subsection id="idc02fd9f1f0c3451e8dfdf4438ee6260d">
              <enum>(iii)</enum>
              <header>Continuous Glucose Monitoring Device; CGM qualified individual</header>
              <paragraph commented="no" display-inline="yes-display-inline" id="id298D455B8A4C4D5299A01599005F72B8">
                <enum>(1)</enum>
                <subparagraph commented="no" display-inline="yes-display-inline" id="idB363423143FD4DA2ABB98646FD43878E">
                  <enum>(A)</enum>
                  <text>The term <term>continuous glucose monitoring device</term>  means a class III medical device approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Food and Drug Administration</cato:entity-ref> that continuously
			 monitors and trends glucose levels in body fluid.</text>
                </subparagraph>
                <subparagraph id="id9A7B6ED31D5640E8B395C34AFAF38512" indent="up2">
                  <enum>(B)</enum>
                  <text>Such term applies to such medical device—</text>
                  <clause id="id21C202593DE94E1483C32A74D919F422">
                    <enum>(i)</enum>
                    <text>as a stand-alone product;</text>
                  </clause>
                  <clause id="id8BD1ED5510434BCB8913BFC9EB9C7BFD">
                    <enum>(ii)</enum>
                    <text>when integrated with an insulin pump; or</text>
                  </clause>
                  <clause id="id2B001F3DB4724F1786E62F1479652669">
                    <enum>(iii)</enum>
                    <text>as an integral component of any other medical device cleared or approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Food and Drug
			 Administration</cato:entity-ref>, such as artificial pancreas device systems.</text>
                  </clause>
                </subparagraph>
                <subparagraph id="idCD61D8F5878A4AB39E4918A0E4EFC809" indent="up2">
                  <enum>(C)</enum>
                  <text>With respect to a continuous glucose monitoring device that is described in clause (ii) or (iii) of
			 subparagraph (B), the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall treat an insulin pump or other
			 medical device that has a continuous glucose monitoring device as an
			 integrated or integral component as a single medical device.</text>
                </subparagraph>
                <subparagraph id="id20BD7A99306640BC9713B5E9ABD0E057" indent="up2">
                  <enum>(D)</enum>
                  <text>Such term includes components, accessories, and supplies that are necessary and related to the
			 operation of the class III medical device, such as sensors, transmitters,
			 receivers, and requisite software.</text>
                </subparagraph>
              </paragraph>
              <paragraph id="id711f201e5a5f4d85a83ee3936b43f9ec" indent="up1">
                <enum>(2)</enum>
                <text>The term <term>CGM qualified individual</term> means any of the following:</text>
                <subparagraph id="id640c599d3b564cf599da776833212d2d">
                  <enum>(A)</enum>
                  <text>An individual with Type I diabetes—</text>
                  <clause id="id493c9b8c93004291a7922234f15b82b7">
                    <enum>(i)</enum>
                    <text>who is following an intensive insulin treatment regimen that consists of 3 or more insulin
			 injections per day or the use of a subcutaneous insulin infusion pump;</text>
                  </clause>
                  <clause id="id3aea087ccb4f49c18e3536270e6d3811">
                    <enum>(ii)</enum>
                    <text>subject to paragraph (3), whose attending physician certifies that the individual’s condition
			 cannot be safely and effectively managed with self-monitoring of blood
			 glucose; and</text>
                  </clause>
                  <clause id="ide4ec2cfb2f904cdf9a7516d2ea4a941b">
                    <enum>(iii)</enum>
                    <text>who—</text>
                    <subclause id="idfba50e81806e4406819869221d890d92">
                      <enum>(I)</enum>
                      <text>has been unable to achieve optimum glycemic control in accordance with evidence-based guidelines;
			 or</text>
                    </subclause>
                    <subclause id="idf3d39fdf4b544980ad49356fbd0f536f">
                      <enum>(II)</enum>
                      <text>has experienced hypoglycemia unawareness or frequent hypoglycemic episodes.</text>
                    </subclause>
                  </clause>
                </subparagraph>
                <subparagraph id="id9a098d080dfd40c7ad6c55ba93c4dac2">
                  <enum>(B)</enum>
                  <text>An individual not described in subparagraph (A) who meets such other medical criteria as the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may specify for the furnishing of a continuous glucose
			 monitoring device based on available medical evidence and taking into
			 account any anticipated pathway to the development of artificial pancreas
			 device systems.</text>
                </subparagraph>
                <subparagraph id="idce9b3e03108f40cd9905c1ce45080dc4">
                  <enum>(C)</enum>
                  <text>An individual with diabetes who has been regularly using a continuous glucose monitoring device
			 before becoming entitled to, or enrolling in, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/pt:A">part A</cato:entity-ref>, or enrolling in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/pt:B">part
			 B</cato:entity-ref>, or both.</text>
                </subparagraph>
              </paragraph>
              <paragraph id="id1f053bad57fa473db9cfbdb302702772" indent="up1">
                <enum>(3)</enum>
                <text>For purposes of a certification by an attending physician described in paragraph (2)(A)(ii), such
			 certification shall not be required more frequently than once every 3
			 years.</text>
              </paragraph>
            </subsection>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
      </subsection>
      <subsection id="id5c1b376d81a2447f9f8ddd2a89e0cb36">
        <enum>(b)</enum>
        <header>Payment</header>
        <paragraph id="id0335961b3778404d96fb660bff765900">
          <enum>(1)</enum>
          <header>In general</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Social Security Act/s:1833/ss:a/p:1">Section 1833(a)(1) of the Social Security Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">
              <cato:entity-ref entity-type="uscode" value="usc/42/1395l/a/1">42 U.S.C. 1395l(a)(1)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended—</text>
          <subparagraph id="id03791EA950104805BD7A820DCD0E3AE4">
            <enum>(A)</enum>
            <text>by striking <quote>and</quote> before <quote>(Z)</quote>; and</text>
          </subparagraph>
          <subparagraph id="idB0E8C7BD2C404A50B1C1A5A6A392F45A">
            <enum>(B)</enum>
            <text>by inserting before the semicolon at the end the following: <quote>, and (AA) with respect to
			 continuous glucose monitoring devices under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1861/ss:s/p:2/sp:GG" proposed="true">section
			 1861(s)(2)(GG)</cato:entity-ref>), the amount paid shall be an amount equal to 80 percent of
			 the amount determined under the fee schedule established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1834/ss:p" proposed="true">section
			 1834(p)</cato:entity-ref>
              </quote>.</text>
          </subparagraph>
        </paragraph>
        <paragraph id="idd5f6c6b165614afbbf591dfdc03d9ea9">
          <enum>(2)</enum>
          <header>Conforming amendment</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Social Security Act/s:1834">Section 1834 of the Social Security Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">
              <cato:entity-ref entity-type="uscode" value="usc/42/1395m">42 U.S.C. 1395m</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by adding at the end the
			 following new subsection:</text>
          <quoted-block display-inline="no-display-inline" id="id64a89a40c61441a19bd452d4e0c4ef46" style="OLC">
            <subsection id="id09154604fe624f029f577f75e62c7d76">
              <enum>(p)</enum>
              <header>Fee schedule for continuous glucose monitoring devices</header>
              <paragraph id="idaf7b46bf13ce41f6a66038a9923bcf08">
                <enum>(1)</enum>
                <header>Establishment</header>
                <subparagraph id="idf1f40b97405f47baa16fa28eda925500">
                  <enum>(A)</enum>
                  <header>In general</header>
                  <text>With respect to continuous glucose monitoring devices (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1861/ss:iii/p:1" proposed="true">section 1861(iii)(1)</cato:entity-ref>)
			 furnished during a year, the amount of payment under this part for such
			 devices shall be determined under a fee schedule established by the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in accordance with this subsection.</text>
                </subparagraph>
                <subparagraph id="idef502c1ecc73449c9a2ff2768c452403">
                  <enum>(B)</enum>
                  <header>Clarification of application of fee schedule to devices having CGM as an integral component</header>
                  <text>Payment shall be calculated and made under the fee schedule established under this subsection for
			 any insulin pump or other medical device that has a continuous glucose
			 monitoring device as an integrated or integral component.</text>
                </subparagraph>
              </paragraph>
              <paragraph id="idebdd563e68e14fdb929327e1d876f9cd">
                <enum>(2)</enum>
                <header>Initial payment rate</header>
                <subparagraph id="id53134c9a5fb74ba89111b2186b027389">
                  <enum>(A)</enum>
                  <header>In general</header>
                  <text>With respect to each distinct type of continuous glucose monitoring device, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
			 establish an initial payment rate under the fee schedule established under
			 this subsection for the first year, which may be a partial year, during
			 which payment may be made for such continuous glucose monitoring device
			 under this part.</text>
                </subparagraph>
                <subparagraph id="id8115c31c60b94d778afa00149b6d4c16">
                  <enum>(B)</enum>
                  <header>Data</header>
                  <text>With respect to a continuous glucose monitoring device, the initial payment rate under subparagraph
			 (A) shall—</text>
                  <clause id="id4AE03035F2774108A6BD8D805A4057BB">
                    <enum>(i)</enum>
                    <text>reflect market rates for such device; and</text>
                  </clause>
                  <clause id="idDC76C9F001814BE4B2BB26E53D84643B">
                    <enum>(ii)</enum>
                    <text>take into
			 account the most recent available data on prices for such device.</text>
                  </clause>
                </subparagraph>
                <subparagraph id="idaef28fd2b940469898d55fc958b77f2a">
                  <enum>(C)</enum>
                  <header>Accounting for differences in functionalities among various CGM devices</header>
                  <text>For purposes of the initial payment rates established under subparagraph (A), the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
			 establish a new HCPCS code for each distinct type of class III medical
			 device cleared or approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Food and Drug Administration</cato:entity-ref> that
			 includes a continuous glucose monitoring device, such as a medical device
			 described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1861/ss:iii/p:1/sp:B/cl:ii" proposed="true">clause (ii)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1861/ss:iii/p:1/sp:B/cl:iii" proposed="true">(iii) of section 1861(iii)(1)(B)</cato:entity-ref>.	Such HCPCS
			 codes shall distinguish among the different functionalities of such
			 devices in a manner that reflects the classifications of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Food and Drug
			 Administration</cato:entity-ref> in clearing or approving such devices.</text>
                </subparagraph>
              </paragraph>
              <paragraph commented="no" display-inline="no-display-inline" id="idfcca5ca2a22f4ef2a03ca8aa88880969">
                <enum>(3)</enum>
                <header display-inline="yes-display-inline">Updates to payment rates</header>
                <text display-inline="yes-display-inline">With respect to each year beginning after the year, or partial year, referred to in paragraph
			 (2)(A)
			 during which an initial payment rate is established for a distinct
			 continuous glucose monitoring device, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall provide for
			 annual updates to the payment rate under the fee schedule established
			 under this subsection for each such device for the preceding year by the
			 percentage increase in the consumer price index for all urban consumers
			 (United States city average) for the 12-month period ending with June of
			 the preceding year.</text>
              </paragraph>
              <paragraph id="id8ac7db4597c3487a9c40a98b68c9157c">
                <enum>(4)</enum>
                <header>Adjustment for geographic variations</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall provide for adjustments to the payment rates under the fee schedule established
			 under this subsection to take into account geographic variations in the
			 prices of continuous glucose monitoring devices.</text>
              </paragraph>
            </subsection>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
      </subsection>
      <subsection id="id654c5699fcbd42e99fb8acdd620ff122">
        <enum>(c)</enum>
        <header>Ensuring beneficiary access to appropriate components</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Social Security Act/s:1847/ss:a">Section 1847(a) of the Social Security Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-3">
              <cato:entity-ref entity-type="uscode" value="usc/42/1395w–3/a">
            42 U.S.C. 1395w–3(a)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by adding at the end
			 the following new paragraph:</text>
        <quoted-block display-inline="no-display-inline" id="id262ef288bf3349baa85b1bf7ddd27b07" style="OLC">
          <paragraph id="id8d1f45337aad4cfea28a6eafb0749894">
            <enum>(8)</enum>
            <header>Ensuring beneficiary access to appropriate components</header>
            <subparagraph id="id93440d0ebcef41ac9ea7cf46ac8ccd0a">
              <enum>(A)</enum>
              <header>In general</header>
              <text>In carrying out the programs under this section with respect to glucose meters required for
			 continuous glucose monitoring devices (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1861/ss:iii/p:1" proposed="true">section 1861(iii)(1)</cato:entity-ref>)
			 that are furnished to CGM qualified individuals (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1861/ss:iii/p:2" proposed="true">section
			 1861(iii)(2)</cato:entity-ref>), the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall ensure that such CGM qualified
			 individuals are furnished the brand of diabetic testing supplies (as
			 defined in subparagraph (B)) that function with such continuous glucose
			 monitoring devices, such as in the case where there is only one brand of
			 glucose meter that is compatible with a particular continuous glucose
			 monitoring device.</text>
            </subparagraph>
            <subparagraph id="idf901fc5ca9c54aafabac237f42d25c07">
              <enum>(B)</enum>
              <header>Definition</header>
              <text>In this paragraph, the term <term>diabetic testing supplies</term> means glucose meters and diabetic testing strips.</text>
            </subparagraph>
          </paragraph>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection>
      <subsection id="id8e5824aa05c64f5db8636e03315683bd">
        <enum>(d)</enum>
        <header>Effective date; Rulemaking</header>
        <paragraph id="idE4126FFD1BD9411192192772AA3FB0AD">
          <enum>(1)</enum>
          <header>Effective date</header>
          <text>The amendments made by this section shall apply to items and services furnished
			 on or after January 1, 2015.</text>
        </paragraph>
        <paragraph id="idDE0B6F20551E4C0C9A54D0339A45B64C">
          <enum>(2)</enum>
          <header>Rulemaking</header>
          <subparagraph id="idE61C442A4FEC4BFF8316CB2A02990965">
            <enum>(A)</enum>
            <header>In general</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref> (in this paragraph referred to as the <quote>Secretary</quote>) shall implement the amendments made by this section through notice and comment rulemaking.</text>
          </subparagraph>
          <subparagraph id="id83361649e5d04cb8af7424371d4b2d8e">
            <enum>(B)</enum>
            <header>Consultation</header>
            <text>As part of the rulemaking process under subparagraph (A), the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consult with national
			 organizations representing individuals with diabetes, physicians with
			 relevant clinical expertise in endocrinology, and other relevant
			 stakeholders to develop clinical criteria for the determination of whether
			 an individual qualifies as having Type I diabetes under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1861/ss:iii/p:2/sp:A" proposed="true">section
			 1861(iii)(2)(A) of the Social Security Act</cato:entity-ref>, as added by subsection (a)(2).
			  Not later than 60 days after the date of enactment of this Act, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall convene a meeting of those stakeholders to develop
			 consensus recommendations for such clinical criteria. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
			 take such recommendations into account in implementing the amendments made
			 by this section.</text>
          </subparagraph>
        </paragraph>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>